Trials / Terminated
TerminatedNCT00836043
Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia
Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia (CLL)
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 6 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will collect data on safety, effectiveness and patient acceptance of MabCampath treatment under daily life conditions.
Detailed description
As of 29 May 2009, the clinical trial sponsor is Genzyme Corporation. NOTE: This study was originally posted by sponsor Schering AG, Germany, which was subsequently renamed to Bayer Schering Pharma AG, Germany.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alemtuzumab (MabCampath) | Intravenous therapy according to product information. |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2009-02-04
- Last updated
- 2013-12-03
Locations
3 sites across 3 countries: Bosnia and Herzegovina, Israel, North Macedonia
Source: ClinicalTrials.gov record NCT00836043. Inclusion in this directory is not an endorsement.